Terms: = Prostate cancer AND ABL1, p150, 25, ENSG00000097007, P00519, v-abl, bcr/abl, JTK7, c-ABL, ABL, BCR-ABL AND Clinical Outcome
93 results:
1. Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence.
Tamburo M; Buffettino E; Pepe P; Marletta G; Pepe L; Cosentino S; Ippolito M; Pennisi M; Marletta F
Anticancer Res; 2024 May; 44(5):2205-2210. PubMed ID: 38677723
[TBL] [Abstract] [Full Text] [Related]
2. Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant prostate cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
van der Zande K; Tutuhatunewa-Louhanepessy RD; Hamberg P; Ras S; de Feijter JM; Dezentjé VO; Broeks A; Cornelissen S; Beeker A; van der Noort V; Zwart W; Bergman AM
Clin Genitourin Cancer; 2024 Apr; 22(2):445-453.e1. PubMed ID: 38246830
[TBL] [Abstract] [Full Text] [Related]
3. Whole exome germline sequencing in early-onset prostate cancer patients: Genomic findings and clinical outcomes.
Siegelmann-Danieli N; Neiman V; Bareket-Samish A; Berger R; Peretz A; Alapi H; Tsur E; Patalon T; Beller D; Rimler G; Chodick G; Shohat M
Prostate; 2024 Jan; 84(1):39-46. PubMed ID: 37842866
[TBL] [Abstract] [Full Text] [Related]
4. Early biochemical and radiographic response after one cycle of [
Cytawa W; Hendel R; Tomasik B; Weinzierl FX; Bley T; Jassem J; Schirbel A; Buck AK; Bundschuh RA; Hartrampf PE; Werner RA; Lapa C
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3765-3776. PubMed ID: 37474735
[TBL] [Abstract] [Full Text] [Related]
5. Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant prostate cancer.
Omlin A; Cathomas R; von Amsberg G; Reuter C; Feyerabend S; Loidl W; Boegemann M; Lorch A; Heidenreich A; Tsaur I; Larcher-Senn J; Buck SAJ; Mathijssen RHJ; Jaehde U; Gillessen S; Joerger M
Clin Cancer Res; 2023 May; 29(10):1887-1893. PubMed ID: 36917691
[TBL] [Abstract] [Full Text] [Related]
6. Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response.
Kafka M; Burtscher T; Fritz J; Schmitz M; Bektic J; Ladurner M; Horninger W; Heidegger I
World J Urol; 2023 Aug; 41(8):2043-2050. PubMed ID: 36287244
[TBL] [Abstract] [Full Text] [Related]
7. Response to [ 177 Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases.
Zisser L; Yu J; Oszwald A; Wollenweber T; Kretschmer-Chott E; Grubmüller B; Kramer G; Shariat SF; Mitterhauser M; Vraka C; Hacker M; Haug AR; Rasul S
Nucl Med Commun; 2022 Nov; 43(11):1113-1120. PubMed ID: 36120814
[TBL] [Abstract] [Full Text] [Related]
8. Molecular mechanisms underlying the development of neuroendocrine prostate cancer.
Liu S; Alabi BR; Yin Q; Stoyanova T
Semin Cancer Biol; 2022 Nov; 86(Pt 3):57-68. PubMed ID: 35597438
[TBL] [Abstract] [Full Text] [Related]
9. Impact of prior cancer on the overall survival of patients with nasopharyngeal carcinoma.
Wang X; Wang Z; Chen Y; Lin Q; Chen H; Lin Y; Lu L; Zheng P; Chen X
Am J Otolaryngol; 2022; 43(1):103235. PubMed ID: 34563802
[TBL] [Abstract] [Full Text] [Related]
10. Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients.
Hansum T; Hollemans E; Verhoef EI; Bangma CH; Rietbergen J; Osanto S; Pelger RCM; van Wezel T; van der Poel H; Bekers E; Helleman J; Remmers S; van Leenders GJLH
Mod Pathol; 2021 Nov; 34(11):2064-2070. PubMed ID: 34175896
[TBL] [Abstract] [Full Text] [Related]
11. aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in
Nickols N; Anand A; Johnsson K; Brynolfsson J; Borreli P; Parikh N; Juarez J; Jafari L; Eiber M; Rettig M
J Nucl Med; 2022 Feb; 63(2):233-239. PubMed ID: 34049980
[TBL] [Abstract] [Full Text] [Related]
12. Moderate hypofractionated post-prostatectomy radiation therapy is feasible and well tolerated: experience from a single tertiary cancer centre.
Valero J; Montero A; Hernando O; Izquierdo M; Sánchez E; García-Aranda M; López M; Ciérvide R; Martí J; Álvarez B; Alonso R; Chen-Zhao X; Fernández-Letón P; Rubio C
Clin Transl Oncol; 2021 Jul; 23(7):1452-1462. PubMed ID: 33433839
[TBL] [Abstract] [Full Text] [Related]
13. Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer.
Kwan KH; Burvenich IJG; Centenera MM; Goh YW; Rigopoulos A; Dehairs J; Swinnen JV; Raj GV; Hoy AJ; Butler LM; Scott AM; White JM; Ackermann U
Nucl Med Biol; 2021 Feb; 93():37-45. PubMed ID: 33310350
[TBL] [Abstract] [Full Text] [Related]
14. clinical outcome of surgical management for symptomatic metastatic spinal cord compression from prostate cancer.
Miyoshi Y; Kawahara T; Yao M; Uemura H
BMC Urol; 2020 Sep; 20(1):143. PubMed ID: 32891133
[TBL] [Abstract] [Full Text] [Related]
15. Inter-observer variability of cribriform architecture and percent Gleason pattern 4 in prostate cancer: relation to clinical outcome.
van der Slot MA; Hollemans E; den Bakker MA; Hoedemaeker R; Kliffen M; Budel LM; Goemaere NNT; van Leenders GJLH
Virchows Arch; 2021 Feb; 478(2):249-256. PubMed ID: 32815034
[TBL] [Abstract] [Full Text] [Related]
16. Short fractionation radiotherapy for early prostate cancer in the time of COVID-19: long-term excellent outcomes from a multicenter Italian trial suggest a larger adoption in clinical practice.
Barra S; Guarnieri A; di Monale E Bastia MB; Marcenaro M; Tornari E; Belgioia L; Magrini SM; Ricardi U; Corvò R
Radiol Med; 2021 Jan; 126(1):142-146. PubMed ID: 32415472
[TBL] [Abstract] [Full Text] [Related]
17. clinical outcomes of abiraterone acetate and predictors of its treatment duration in metastatic castration-resistant prostate cancer: Real-world experience in the Southeast Asian cohort.
Lim J; Amantakul A; Shariff N; Lojanapiwat B; Alip A; Ong TA; Thevarajah S; Ahmayuddin F; Mathew A; Sriplakich S; Vuthiwong J; Chong FLT; Saad M
Cancer Med; 2020 Jul; 9(13):4613-4621. PubMed ID: 32374087
[TBL] [Abstract] [Full Text] [Related]
18. Androgens and Overall Survival in Patients With Metastatic Castration-resistant prostate cancer Treated With Docetaxel.
Ryan CJ; Dutta S; Kelly WK; Middleberg R; Russell C; Morris MJ; Taplin ME; Halabi S;
Clin Genitourin Cancer; 2020 Jun; 18(3):222-229.e2. PubMed ID: 32273234
[TBL] [Abstract] [Full Text] [Related]
19. Early prostate-Specific Antigen Changes and clinical outcome After
Gafita A; Heck MM; Rauscher I; Tauber R; Cala L; Franz C; D'Alessandria C; Retz M; Weber WA; Eiber M
J Nucl Med; 2020 Oct; 61(10):1476-1483. PubMed ID: 32111687
[TBL] [Abstract] [Full Text] [Related]
20. A High Percent Free prostate Specific Antigen in the Setting of Biochemical Recurrence after Radical prostatectomy is Associated with Poorer outcomes: A Validation Study Using Prospectively Collected Biobank Specimens.
Woon DTS; Herrera-Cáceres JO; Goldberg H; Shiakh H; Whelan E; Nason G; Ajib K; Tan GH; Chandrasekar T; Alhunaidi O; Finelli A; Zlotta A; Berlin A; Diamantis E; Fleshner N
J Urol; 2020 Aug; 204(2):289-295. PubMed ID: 32068483
[TBL] [Abstract] [Full Text] [Related]
[Next]